New discovery! Melatonin may be expected to help treat new coronary pneumonia

In a recent study published in the international journal PLoS Biology, scientists from the Cleveland Clinic and others found that melatonin may be available as a new treatment for COVID-19.
melatonin is a hormone molecule that regulates the body's wake-up cycle and is often used as an over-the-counter sleeping pill.
the study, researchers developed a new artificial intelligence platform to help identify potential drugs that could treat COVID-19.
researchers have found that melatonin may be a candidate for COVID-19.
analyzed data from patients registered with the Cleveland Clinic on COVID-19, the researchers said that when adjusting for age, race, smoking history, and complications from multiple diseases, participants who used melatonin or were about 30 percent less likely to test positive for SARS-CoV-2.
noted that for African-Americans, the probability of testing positive for the virus increased from 30 percent to 52 percent if the same variables were adjusted.
researcher Dr Feixiong Cheng said the findings did not mean people could take melatonin on their own without consulting a clinician.
large-scale observational studies and randomized controlled trials in late 2000s were critical to confirming the clinical efficacy of melatonin in PATIENT-19 patients, and we found a correlation in this study, which will be further studied later. In the
article, the researchers used online medical methods and large-scale electronic health records from clinic patients to identify common clinical manifestations and pathological mechanisms between COVID-19 and other diseases, in particular, the closer the researchers measured the proximity between cesod gene whites and the 64 other diseases associated with them in a variety of disease classifications, and the closer they came to the pathological associations between diseases, including malignant cancer, autoimmune diseases, and cardiovascular diseases.
researchers say the high correlation between proteins associated with respiratory distress syndrome and sepsis, two leading causes of death in severe COVID-19 patients, or with a variety of SARS-CoV-2 proteins, may tell researchers that using drugs already approved to treat these respiratory diseases may be able to target biological targets that work together to make some difference in the treatment of COVID-19.
In the end, the researchers found that autoimmune, lung and neurological diseases had significant network approximations to the genetic whiteness of SARS-CoV-2, and identified 34 drugs or candidates for redirection, including melatonin. Cheng, a
researcher, said recent studies have shown that COVID-19 is a systemic disease that affects multiple cell types, tissues and organs, so understanding the complex interactions between viruses and other diseases may be key to uncovering COVID-19-related complications and identifying new redirection drugs.
this paper provides a powerful, comprehensive network medicine strategy that may help researchers predict the manifestations of COVID-19-related diseases and drive scientists to find new and effective therapies.
original source: Yadi Zhou et al. A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19, PLoS Biology (2020). DOI:10.1371/journal.pbio.3000970 This article was originally sourced from Bio Valley, please download Bio Valley APP for more information (